MX2007011493A - Modalidades antiinflamatorias. - Google Patents

Modalidades antiinflamatorias.

Info

Publication number
MX2007011493A
MX2007011493A MX2007011493A MX2007011493A MX2007011493A MX 2007011493 A MX2007011493 A MX 2007011493A MX 2007011493 A MX2007011493 A MX 2007011493A MX 2007011493 A MX2007011493 A MX 2007011493A MX 2007011493 A MX2007011493 A MX 2007011493A
Authority
MX
Mexico
Prior art keywords
inflammatory
inflammatory modalities
modalities
treatment
compounds
Prior art date
Application number
MX2007011493A
Other languages
English (en)
Inventor
Alan James Husband
Catherin Walker
James Michael John
Original Assignee
Novogen Res Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005901475A external-priority patent/AU2005901475A0/en
Application filed by Novogen Res Pty Ltd filed Critical Novogen Res Pty Ltd
Publication of MX2007011493A publication Critical patent/MX2007011493A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Se describen modalidades antiinflamatorias con referencia a compuestos isoflavonoides seleccionados, composiciones conteniendolos y el usote dichos compuestos y/o composiciones en un tratamiento, particularmente para el tratamiento de enfermedades inflamatorias y condiciones relacionadas.
MX2007011493A 2005-03-24 2006-03-24 Modalidades antiinflamatorias. MX2007011493A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2005901475A AU2005901475A0 (en) 2005-03-24 Isflavonoid dimers
US66860905P 2005-04-06 2005-04-06
AU2005905985A AU2005905985A0 (en) 2005-10-28 Pain and anti-inflammatory modalities
PCT/AU2006/000407 WO2006108212A1 (en) 2005-03-24 2006-03-24 Anti-inflammatory modalities

Publications (1)

Publication Number Publication Date
MX2007011493A true MX2007011493A (es) 2008-04-14

Family

ID=37023310

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007011493A MX2007011493A (es) 2005-03-24 2006-03-24 Modalidades antiinflamatorias.

Country Status (15)

Country Link
US (3) US7700644B2 (es)
EP (3) EP1861402B1 (es)
JP (2) JP2008533177A (es)
CN (2) CN101203219B (es)
AT (1) ATE496921T1 (es)
AU (2) AU2006235194A1 (es)
CA (2) CA2602541A1 (es)
DE (1) DE602006019832D1 (es)
ES (1) ES2360130T3 (es)
HK (1) HK1119557A1 (es)
IL (2) IL186217A0 (es)
MX (1) MX2007011493A (es)
NO (2) NO20075368L (es)
NZ (2) NZ561574A (es)
WO (2) WO2006099681A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029995A1 (ja) * 2008-09-11 2010-03-18 協和発酵キリン株式会社 疼痛治療剤
JP6115303B2 (ja) * 2012-05-18 2017-04-19 Jnc株式会社 隣接基としてカルボニル基を有するフェノール化合物およびその用途
KR101533197B1 (ko) * 2014-09-18 2015-07-02 성균관대학교산학협력단 부테인을 포함하는 부종의 예방 또는 치료용 조성물
KR101539180B1 (ko) * 2014-09-18 2015-07-24 성균관대학교산학협력단 플라보노이드계 화합물을 포함하는 림프부종의 예방 또는 치료용 조성물
US10160740B2 (en) 2015-03-20 2018-12-25 The Board Of Trustees Of The Leland Stanford Junior University Carbonate-promoted carboxylation reactions for the synthesis of valuable organic compounds
AU2017247008B2 (en) 2016-04-06 2022-04-07 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
JP2019513826A (ja) 2016-04-06 2019-05-30 ノクソファーム リミティド 放射線療法の改善
RU2649119C1 (ru) * 2017-02-27 2018-03-29 Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук (ИрИХ СО РАН) Средство для профилактики и лечения язвенного колита
WO2019051548A1 (en) * 2017-09-15 2019-03-21 Norbio No. 2 Pty Ltd TREATMENT OF NEURO-INFLAMMATION
WO2020051644A1 (en) * 2018-09-13 2020-03-19 Norbio No. 2 Pty Ltd Treatment of peripheral nervous tissue inflammation
AU2021247415A1 (en) 2020-03-30 2022-09-29 Noxopharm Limited Methods for the treatment of inflammation associated with infection
WO2021195698A1 (en) * 2020-03-30 2021-10-07 Noxopharm Limited Methods for the treatment of inflammation associated with infection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967362A (ja) * 1995-09-01 1997-03-11 Sankyo Co Ltd ５α−還元酵素阻害剤ビスイソフラボン類
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
WO1999024426A1 (fr) * 1997-11-11 1999-05-20 Nikken Chemicals Co., Ltd. Derive de n-hydroxyuree et medicament le contenant
US6518301B1 (en) * 1999-04-16 2003-02-11 Astrazeneca Ab Estrogen receptor-β ligands
AUPQ266199A0 (en) * 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
CA2407469A1 (en) * 2000-05-15 2001-11-22 Merck Frosst Canada & Co. Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
AUPR363301A0 (en) * 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
WO2002074307A1 (en) * 2001-03-16 2002-09-26 Novogen Research Pty Ltd Treatment of restenosis
CN1398586A (zh) * 2001-07-26 2003-02-26 中国人民解放军军事医学科学院放射医学研究所 新的取代庚酸衍生物治疗支气管哮喘和慢性阻塞性肺病
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
AU2002952453A0 (en) * 2002-11-01 2002-11-21 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof
NZ546150A (en) * 2003-11-19 2010-04-30 Novogen Res Pty Ltd Radiosensitization using isoflavones
WO2006032085A1 (en) * 2004-09-21 2006-03-30 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy

Also Published As

Publication number Publication date
EP1861402A1 (en) 2007-12-05
EP1861402B1 (en) 2011-01-26
NZ561573A (en) 2010-05-28
CN101184756A (zh) 2008-05-21
WO2006099681A1 (en) 2006-09-28
NO20075367L (no) 2007-11-27
EP1861090A1 (en) 2007-12-05
AU2006227555A1 (en) 2006-09-28
CA2602549A1 (en) 2006-10-19
EP1861402A4 (en) 2009-12-30
US7700644B2 (en) 2010-04-20
JP2008537545A (ja) 2008-09-18
AU2006235194A1 (en) 2006-10-19
DE602006019832D1 (de) 2011-03-10
WO2006108212A1 (en) 2006-10-19
CA2602541A1 (en) 2006-09-28
EP2526941A1 (en) 2012-11-28
IL186217A0 (en) 2008-08-07
CN101203219A (zh) 2008-06-18
ES2360130T3 (es) 2011-06-01
US20080306140A1 (en) 2008-12-11
ATE496921T1 (de) 2011-02-15
NO20075368L (no) 2007-12-11
EP1861090A4 (en) 2010-01-06
CN101203219B (zh) 2011-06-15
US20090131513A1 (en) 2009-05-21
IL186218A0 (en) 2008-01-20
JP2008533177A (ja) 2008-08-21
HK1119557A1 (en) 2009-03-13
US20120059176A1 (en) 2012-03-08
NZ561574A (en) 2010-03-26
CN101184756B (zh) 2011-08-03

Similar Documents

Publication Publication Date Title
MX2007011493A (es) Modalidades antiinflamatorias.
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
MY149957A (en) Heterocyclic inhibitors of mek and methods of use thereof
EP1919302B8 (en) Food comprising silicon
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
WO2007115821A3 (en) Organic compounds
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
EA201101522A1 (ru) Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10)
EA201170521A1 (ru) Новые соединения
NO20081636L (no) FAP - inhibitorer
CL2009000200A1 (es) Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
MY147247A (en) Organic compounds and their uses
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
UA85559C2 (en) Aminobenzophenone compounds
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
WO2009077471A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
TW200630367A (en) Substituted adenines and the uses thereof
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
TW200700064A (en) Novel compounds
TW200700358A (en) Organic compounds
TNSN08496A1 (en) Aminothiazoles and their uses
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη